17Q1 Stock Overview
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Pharmaron Beijing Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.09 |
| 52 Week High | CN¥2.72 |
| 52 Week Low | CN¥0.89 |
| Beta | 0.62 |
| 1 Month Change | 5.83% |
| 3 Month Change | -6.84% |
| 1 Year Change | -56.97% |
| 3 Year Change | -85.40% |
| 5 Year Change | n/a |
| Change since IPO | -50.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 17Q1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 17.2% | 2.4% | 1.2% |
| 1Y | -57.0% | -10.6% | 2.0% |
Return vs Industry: 17Q1 underperformed the German Life Sciences industry which returned -10.6% over the past year.
Return vs Market: 17Q1 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 17Q1 volatility | |
|---|---|
| 17Q1 Average Weekly Movement | 11.5% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 17Q1 has not had significant price volatility in the past 3 months.
Volatility Over Time: 17Q1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 20,295 | Boliang Lou | www.pharmaron.com |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services.
Pharmaron Beijing Co., Ltd. Fundamentals Summary
| 17Q1 fundamental statistics | |
|---|---|
| Market cap | €4.18b |
| Earnings (TTM) | €191.32m |
| Revenue (TTM) | €1.48b |
24.0x
P/E Ratio3.1x
P/S RatioIs 17Q1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 17Q1 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.48b |
| Cost of Revenue | CN¥7.47b |
| Gross Profit | CN¥4.01b |
| Other Expenses | CN¥2.53b |
| Earnings | CN¥1.48b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.83 |
| Gross Margin | 34.94% |
| Net Profit Margin | 12.92% |
| Debt/Equity Ratio | 58.3% |
How did 17Q1 perform over the long term?
See historical performance and comparison